AbbVie Drops Autoimmune Candidate, Prioritizes Skyrizi and Rinvoq

While reporting positive third-quarter financials, AbbVie announced it is halting the development of cedirogant (ABBV-157), while also providing updates on Skyrizi, Rinvoq and Humira.

Cedirogant is an oral RORg inverse agonist for autoimmune diseases, and more specifically, psoriasis, that was jointly discovered and developed with France’s Inventiva.